Sulfadiazine
Sulfadiazine is a sulfonamide-type antibiotic that works by inhibiting bacterial folic acid synthesis, making it effective against a range of susceptible gram-positive and gram-negative bacteria. It is used to treat various bacterial infections including urinary tract infections, respiratory tract infections, and is sometimes used in combination with other medications for specific conditions.
Sulfadiazine is a sulfonamide antibiotic used to treat various bacterial infections by inhibiting folic acid synthesis in susceptible organisms.
Key facts at a glance
- ATC
- J01EC02
- RxNorm
- 10171
- Generic
- Sulfadiazine
- Class
- atc-j01
- Brands
- Rebalance, Equisul SDT, Uniprim
- Availability
- rx
- Pregnancy
- B
- Lactation
- safe
- Routes
- oral
- Forms
- suspension, powder, solution, tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treatment of infections caused by susceptible strains of Streptococcus, Staphylococcus, Escherichia coli, Klebsiella, and certain gram-negative organisms. Historically used for urinary tract infections, otitis media, bronchitis, and other respiratory infections. May also be used as part of combination therapy for toxoplasmosis.
Sulfadiazine is a competitive inhibitor of dihydropteroate synthase, blocking the incorporation of para-aminobenzoic acid (PABA) into dihydrofolic acid. This bacteriostatic action prevents bacterial synthesis of folic acid, which is essential for nucleic acid production and bacterial growth.
Cross-reactivity may occur in patients with sulfonamide (sulfa) allergies. Adequate fluid intake is required to prevent crystalluria. May cause blood dyscrasias; regular monitoring may be needed. Not recommended in late pregnancy or for infants under 2 months. May increase risk of kernicterus in newborns.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy